(Total Views: 242)
Posted On: 11/06/2018 1:20:04 PM
Post# of 36566
I count 12 PR's since 10/1. That does remind me of the old days. OTOH, I am anxious to see what this 1: 20 dividend is all about and how it impacts the pps.
Beyond that I am willing to keep some money in the game to see what develop re: the Veneto business model. I still don't understand it, but it does provide a source of income. Goldman likes it, too.
I'm also interested in buccal delivery of cannabis. Anecdotally, I have heard people praise its effectiveness in pain management and muscle spasticity. GWPH has used a cannabis molecule for childhood epilepsy that has been approved by the FDA.
Finally, AE37 is still around. What will the Keytruda combo trials show? There are enough potential catalyst to keep us interested, as long as your abp (average buying price isn't in the double digits. That's too much risk and speculation for me.
Beyond that I am willing to keep some money in the game to see what develop re: the Veneto business model. I still don't understand it, but it does provide a source of income. Goldman likes it, too.
I'm also interested in buccal delivery of cannabis. Anecdotally, I have heard people praise its effectiveness in pain management and muscle spasticity. GWPH has used a cannabis molecule for childhood epilepsy that has been approved by the FDA.
Finally, AE37 is still around. What will the Keytruda combo trials show? There are enough potential catalyst to keep us interested, as long as your abp (average buying price isn't in the double digits. That's too much risk and speculation for me.
(0)
(0)
